Literature DB >> 27117349

Development of cell therapy medicinal products by academic institutes.

Sofieke de Wilde1, Henk-Jan Guchelaar1, Carla Herberts2, Mark Lowdell3, Martin Hildebrandt4, Maarten Zandvliet1, Pauline Meij1.   

Abstract

In the rapidly evolving fields of cellular immunotherapy, gene therapy and regenerative medicine, a wide range of promising cell therapy medicinal products are in clinical development. Most products originate from academic research and are explored in early exploratory clinical trials. However, the success rate toward approval for regular patient care is disappointingly low. In this paper, we define strengths and hurdles applying to the development of cell therapy medicinal products in academic institutes, and analyze why only a few promising cell therapies have reached late-stage clinical development. Subsequently, we provide recommendations to stakeholders involved in development of cell therapies to exploit their potential clinical benefit.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27117349     DOI: 10.1016/j.drudis.2016.04.016

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  5 in total

Review 1.  Translational Challenges in Cardiovascular Tissue Engineering.

Authors:  Maximilian Y Emmert; Emanuela S Fioretta; Simon P Hoerstrup
Journal:  J Cardiovasc Transl Res       Date:  2017-03-09       Impact factor: 4.132

Review 2.  Advanced Therapy Medicinal Products and the Changing Role of Academia.

Authors:  Christoph Priesner; Martin Hildebrandt
Journal:  Transfus Med Hemother       Date:  2022-05-16       Impact factor: 4.040

3.  Improving Stem Cell Clinical Trial Design and Conduct: Development of a Quality Assessment Tool for Stem Cell Clinical Trials.

Authors:  Yixuan Li; Li Xie; Jie Wang; Jinghang He; Ying Qian; Weituo Zhang; Zhaohui Wu; Biyun Qian
Journal:  Stem Cells Int       Date:  2020-11-07       Impact factor: 5.443

4.  Clinical development of gene- and cell-based therapies: overview of the European landscape.

Authors:  Sofieke de Wilde; Henk-Jan Guchelaar; Maarten Laurens Zandvliet; Pauline Meij
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-30       Impact factor: 6.698

5.  Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist-a pragmatic tool to accelerate development of cell therapy products.

Authors:  Anjali Nagpal; Austin G Milton; Simon A Koblar; M Anne Hamilton-Bruce
Journal:  Stem Cell Res Ther       Date:  2021-01-29       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.